Skip to main content
. Author manuscript; available in PMC: 2014 Aug 27.
Published in final edited form as: Cell. 2013 Jun 20;153(7):1552–1566. doi: 10.1016/j.cell.2013.05.041

Figure 6. BET bromodomain inhibitors deplete LIC and inhibits progression of T-ALL both in vitro and in vivo.

Figure 6

(a) Histogram depicting c-MycGFP levels in primary Notch1ΔE ires mCherry+c-MycGFP+ splenocytes co-cultured on OP9 stromal cells in the presence of 5 ng/ml IL-7 and either 200 nM JQ-1 or DMSO. (b) Growth of primary mouse T-ALL treated with increasing concentrations of JQ-1 or CPI203 for 72 hours. Calculated EC50 for each compound is shown. (c) Myc mRNA measured by quantitative RT-PCR, in primary mouse T-ALL cells treated with CPI203 for 4 hours at the indicated concentration. (d) Bioluminescent imaging of recipient mice transplanted either Fbxw7+/+ (top) or Fbxw7mut/+ (bottom) Notch1ΔE leukemias and treated with either CPI203 (5 mg kg−1) or vehicle BID for 7 days. (d) Quantification of total bioluminescent counts, each data point representing an individual mouse, before and following 7 days of the indicated treatment.